期刊
NEUROPSYCHOPHARMACOLOGY
卷 28, 期 1, 页码 170-181出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.npp.1300005
关键词
psilocybin; schizophrenia; model psychosis; serotonin; mismatch negativity; working memory; cognition
Previously the NMDA (N-methyl-D-aspartate) receptor (NMDAR) antagonist ketamine was shown to disrupt generation of the auditory event-related potential (ERP) mismatch negativity (MMN) and the performance of an 'AX'-type continuous performance test (AX-CPT)-measures of auditory and visual context-dependent information processing-in a similar manner as observed in schizophrenia. This placebo-controlled study investigated effects of the 5-HT2A receptor agonist psilocybin on the same measures in 18 healthy volunteers. Psilocybin administration induced significant performance deficits in the AX-CPT, but failed to reduce MMN generation significantly. These results indirectly support evidence that deficient MMN generation in schizophrenia may be a relatively distinct manifestation of deficient NMDAR functioning. In contrast, secondary pharmacological effects shared by NMDAR antagonists and the 5-HT2A agonist (ie disruption of glutamatergic neurotransmission) may be the mechanism underlying impairments in AX-CPT performance observed during both psilocybin and ketamine administration. Comparable deficits in schizophrenia may result from independent dysfunctions of 5-HT2A and NMDAR-related neurotransmission.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据